ArticleThe Journal of infectious diseases2015
Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.
Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Vaccination and screening strategies to accelerate cervical cancer elimination in Norway: a model-based analysis.British journal of cancer · 2024Article
- Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis.Preventive medicine · 2021Article
- Sociodemographic Correlates of Human Papillomavirus Vaccine Uptake: Opportunistic and Catch-Up Vaccination in Norway.Cancers · 2021Article
- Article
- Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.BMC infectious diseases · 2019Article
- Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States.Vaccine · 2018Article
- Influencers and preference predictors of HPV vaccine uptake among US male and female young adult college students.Papillomavirus research (Amsterdam, Netherlands) · 2018Article
- Surveillance of Vaccination Coverage among Adult Populations - United States, 2015.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2017Article
- The Interaction between Human Immunodeficiency Virus and Human Papillomaviruses in Heterosexuals in Africa.Journal of clinical medicine · 2015Review
- Vaccination coverage among adults, excluding influenza vaccination - United States, 2013.MMWR. Morbidity and mortality weekly report · 2015Article
- The cost-effectiveness of human papillomavirus vaccine catch-up programs for women.The Journal of infectious diseases · 2015Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundHuman papillomavirus (HPV) vaccines are ideally administered before HPV exposure; therefore, catch-up programs for girls past adolescence have not been readily funded. We evaluated the benefits and cost-effectiveness of a delayed, 1-year female catch-up vaccination program in Norway.
methodsWe calibrated a dynamic HPV transmission model to Norwegian data and projected the costs and benefits associated with 8 HPV-related conditions while varying the upper vaccination age limit to 20, 22, 24, or 26 years. We explored the impact of vaccine protection in women with prior vaccine-targeted HPV infections, vaccine cost, coverage, and natural- and vaccine-induced immunity.
resultsThe incremental benefits and cost-effectiveness decreased as the upper age limit for catch-up increased. Assuming a vaccine cost of $150/dose, vaccination up to age 20 years remained below Norway's willingness-to-pay threshold (approximately $83 000/quality-adjusted life year gained); extension to age 22 years was cost-effective at a lower cost per dose ($50-$75). At high levels of vaccine protection in women with prior HPV exposure, vaccinating up to age 26 years was cost-effective. Results were stable with lower coverage.
conclusionsHPV vaccination catch-up programs, 5 years after routine implementation, may be warranted; however, even at low vaccine cost per dose, the cost-effectiveness of vaccinating beyond age 22 years remains uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.